SGLT2 deletion improves glucose homeostasis and preserves pancreatic β-cell function

Diabetes

Volumn 60, Issue 3, 2011, Pages 890-898

  Jurczak, Michael J ^a   Lee, Hui Young ^a   Birkenfeld, Andreas L ^a   Jornayvaz, Francois R ^a   Frederick, David W ^a   Pongratz, Rebecca L ^a   Zhao, Xiaoxian ^a   Moeckel, Gilbert W ^a   Samuel, Varman T ^a   Whaley, Jean M ^b   Shulman, Gerald I ^a   Kibbey, Richard G ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRINKING; FEEDING; GLUCOSE CLAMP TECHNIQUE; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; GLUCOSURIA; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; KNOCKOUT MOUSE; LIPID DIET; MOUSE; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; DIETARY FATS; GLUCOSE; HOMEOSTASIS; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; KIDNEY; MICE; MICE, KNOCKOUT; OBESITY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 79952404360     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-1328     Document Type: Article

References (36)

1. Chao EC, Henry RR. SGLT2 inhibition - a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010;9:551-559
2. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010;95:34-42
3. Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Pflugers Arch 2004;447:510-518
4. Pajor AM, Hirayama BA, Wright EM. Molecular evidence for two renal Na+/glucose cotransporters. Biochim Biophys Acta 1992;1106:216-220
5. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994;93: 397-404
6. Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011;22:104-112
7. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 2001;104:517-529
8. Federici M, Hribal M, Perego L, et al. High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes 2001;50:1290-1301
9. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Betacell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-110
10. Donath MY, Gross DJ, Cerasi E, Kaiser N. Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 1999;48:738-744
11. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987;80:1037-1044
12. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79:1510-1515
13. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008;327:268-276
14. Fujimori Y, Katsuno K, Ojima K, et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009;609:148-154
15. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57:1723-1729
16. Katsuno K, Fujimori Y, Ishikawa-Takemura Y, Isaji M. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KKA( y) mice. Eur J Pharmacol 2009;618:98-104
17. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85:520-526
18. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009;85:513-519
19. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-657
20. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009;32:1656-1662
21. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223-2233
22. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-2224
23. Choi CS, Savage DB, Abu-Elheiga L, et al. Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc Natl Acad Sci USA 2007;104:16480-16485
24. Pongratz RL, Kibbey RG, Kirkpatrick CL, et al. Mitochondrial dysfunction contributes to impaired insulin secretion in INS-1 cells with dominant-negative mutations of HNF-1alpha and in HNF-1alpha-deficient islets. J Biol Chem 2009;284:16808-16821
25. Jurczak MJ, Danos AM, Rehrmann VR, Allison MB, Greenberg CC, Brady MJ. Transgenic overexpression of protein targeting to glycogen markedly increases adipocytic glycogen storage in mice. Am J Physiol Endocrinol Metab 2007;292:E952-E963
26. Bonner-Weir S, Trent DF, Weir GC. Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest 1983;71: 1544-1553
27. Finegood DT, McArthur MD, Kojwang D, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001;50:1021-1029
28. Arakawa K, Ishihara T, Oku A, et al. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 2001;132:578-586
29. Unger RH, Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia 1985;28:119-121
30. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000;106:473-481
31. Zinker B, Mika A, Nguyen P, et al. Liver-selective glucocorticoid receptor antagonism decreases glucose production and increases glucose disposal, ameliorating insulin resistance. Metabolism 2007;56:380-387
32. Gibbs EM, Stock JL, McCoid SC, et al. Glycemic improvement in diabetic db/db mice by overexpression of the human insulin-regulatable glucose transporter (GLUT4). J Clin Invest 1995;95:1512-1518
33. Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003;14:2873-2882
34. Calado J, Sznajer Y, Metzger D, et al. Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrol Dial Transplant 2008;23:3874-3879
35. Francis J, Zhang J, Farhi A, Carey H, Geller DS. A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria. Nephrol Dial Transplant 2004;19:2893-2895
36. Ly JP, Onay T, Sison K, Sivaskandarajah G, et al. Sweet Pee model for Sglt2 mutation. J Am Soc Nephrol 2011;22:113-123